ArticleNature2019
Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer.
Abstract read
In one paragraph
Article in Nature, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 208 papers.
0numbers the graph read from it
0cells of the map it votes in
208citing papers in PubMed
26.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
208 citing papers in PubMed, 287 citations in OpenAlex.
- The molecular heterogeneity and clinical impact of genomic driver alterations in prostate cancer.Nature communications · 2026Article
- Targeting the Androgen Receptor and Associated Cofactors in Prostate Cancer: Novel Approaches and Future Perspectives.International journal of molecular sciences · 2026Review
- Article
- Multi-omics dissection of FOXA1 reveals cancer-type-specific transcriptional networks and functional risk variants.iScience · 2026Article
- FOXA1 is a highly sensitive diagnostic marker for prostate cancer including small cell carcinoma of the prostate.Histopathology · 2026Article
- A ligandable PNT domain establishes ERG as a directly targetable oncogenic driver in prostate cancer.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Identification of targets of clinical FOXA1 mutants involved in EMT and immune suppression in prostate cancer.Communications biology · 2026Article
- Genomic Determinants of Lethality and Therapeutic Vulnerability in Castration-Resistant Prostate Cancer.bioRxiv : the preprint server for biology · 2026Article
- Molecular determinants of AR-enhancer interaction and cistrome reprogramming in prostate cancer progression.Endocrine-related cancer · 2026Review
- 3D genome architecture and epigenetic regulation of lineage identity in advanced prostate cancer.Endocrinology · 2026Review
- IDH1 Mutations Are Associated with Favorable Outcomes in Prostate Cancer.European urology · 2026Article
- DNA Methylation-Based Risk Stratification and Classification of Pediatric Thyroid Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Rewiring Oncogenic Transcriptional Complexes with Domain-ALTeration Chimeras (DALTACs) in Prostate Cancer.bioRxiv : the preprint server for biology · 2026Article
- Connecting multiway enhancer-promoter interactions to changes in gene expression in cancer.bioRxiv : the preprint server for biology · 2026Article
- Morphological abnormalities in the ureter of type XVII collagen-deficient mice.Scientific reports · 2026Article
- Convergent evolution of complex structural variants drives therapy resistance in metastatic prostate cancer.Genome biology · 2026Article
- STAG2 loss amplifies EWS-FLI1-driven microsatellite enhancer activity promoting Ewing sarcoma aggressiveness.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- A Double-Negative Prostate Cancer Subtype Is Vulnerable to SWI/SNF-Targeting Degrader Molecules.Cancer research · 2026Article
- FOXA1 loss drives basal/squamous de-differentiation of prostate cancer and induces an immunosuppressive tumor microenvironment.Nature communications · 2026Article
- Genomic landscape and precision therapy in prostate cancer: current status and future directions.NPJ precision oncology · 2026Review
148 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
17 authors at 4 institutions in 1 country.
Abhijit Parolia *Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
Marcin Cieslik *Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
Shih-Chun ChuMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
Lanbo XiaoMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
Takahiro OuchiMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
Yuping ZhangMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
Xiaoju WangMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
Pankaj VatsMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
Xuhong CaoMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
Sethuramasundaram PitchiayaMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
Fengyun SuMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
Rui WangMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
Felix Y FengHelen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, CA, USA.
Yi-Mi WuMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
Robert J LonigroMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
Dan R RobinsonMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
Arul M ChinnaiyanMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA. arul@umich.edu.
University of Michigan–Ann Arbor · USMichigan Center for Translational Pathology · USHoward Hughes Medical Institute · USUniversity of California, San Francisco · US
Funding
Tissue/InformaticsP50CA186786 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Ganesh S Palapattu · 2014 to 2026
$27.6MExploring Precision Oncology: From Gene Fusions to lncRNAsR35CA231996 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CHINNAIYAN, ARUL M · 2018 to 2024
$6.4MDiscovery and qualification of transcriptomic biomarkers for the early detection of aggressive prostate cancerU01CA214170 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CHINNAIYAN, ARUL M · 2016 to 2021
$3.3MExploring mechanisms of transcriptional and chromatin dysregulation in cancerF99CA245825 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI PAROLIA, ABHIJIT · 2019 to 2020
$76kHoward Hughes Medical InstituteNCI NIH HHS F99 CA245825NCI NIH HHS P50 CA186786NCI NIH HHS R35 CA231996NCI NIH HHS U01 CA214170
Abstract
abtractForkhead box A1 (FOXA1) is a pioneer transcription factor that is essential for the normal development of several endoderm-derived organs, including the prostate gland
Indexed as
Cell Line, TumorChromatinGene Expression Regulation, NeoplasticGenome, HumanHepatocyte Nuclear Factor 3-alphaHumansMaleModels, MolecularMutationNeoplasm MetastasisProstatic NeoplasmsProtein DomainsReceptors, AndrogenWnt Signaling PathwayAR protein, humanChromatinFOXA1 protein, humanHepatocyte Nuclear Factor 3-alphaReceptors, Androgen
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.